Patients with hormone-positive breast cancer showed no benefit from BP. Those with hormone-negative, however, showed what researchers called "significant prolonged survival" from the drug. Disease-free survival was more than two years, with fewer than three metastatic sites. Patients received an average of 17.7 cycles of BP.
Download a PDF of the research here.